Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12–49.
Google Scholar
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63.
Google Scholar
Wang S, Zheng Y, Yang F, Zhu L, Zhu X-Q, Wang Z-F, et al. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduct Target Ther. 2021;6:249.
Google Scholar
Jain A, Bhardwaj V. Therapeutic resistance in pancreatic ductal adenocarcinoma: current challenges and future opportunities. World J Gastroenterol. 2021;27:6527–50.
Google Scholar
Palma AM, Vudatha V, Peixoto ML, Madan E. Tumor heterogeneity: an oncogenic driver of PDAC progression and therapy resistance under stress conditions. Adv Cancer Res. 2023;159:203–49.
Google Scholar
Chan-Seng-Yue M, Kim JC, Wilson GW, Ng K, Figueroa EF, O’Kane GM, et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat Genet. 2020;52:231–40.
Google Scholar
Li Y, Tang S, Shi X, Lv J, Wu X, Zhang Y, et al. Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer. Cell Rep Med. 2023;4:101162.
Google Scholar
Daemen A, Peterson D, Sahu N, McCord R, Du X, Liu B, et al. Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors. Proc Natl Acad Sci. 2015;112:E4410–E4417.
Google Scholar
Karasinska JM, Topham JT, Kalloger SE, Jang GH, Denroche RE, Culibrk L, et al. Altered gene expression along the glycolysis-cholesterol synthesis axis is associated with outcome in pancreatic cancer. Clin Cancer Res. 2020;26:135–46.
Google Scholar
Li X, Du Y, Jiang W, Dong S, Li W, Tang H, et al. Integrated transcriptomics, proteomics and metabolomics-based analysis uncover TAM2-associated glycolysis and pyruvate metabolic remodeling in pancreatic cancer. Front Immunol. 2023;14:1170223.
Google Scholar
Fan Z, Xiao Y, Du Y, Zhang Y, Zhou W. Pancreatic cancer subtyping—the keystone of precision treatment. Front Immunol. 2025;16:1563725.
Google Scholar
Espiau-Romera P, Courtois S, Parejo-Alonso B, Sancho P. Molecular and metabolic subtypes correspondence for pancreatic ductal adenocarcinoma classification. J Clin Med. 2020;9:4128.
Google Scholar
Gaude E, Schmidt C, Gammage PA, Dugourd A, Blacker T, Chew SP, et al. NADH shuttling couples cytosolic reductive carboxylation of glutamine with glycolysis in cells with mitochondrial dysfunction. Mol Cell. 2018;69:581–593.e7.
Google Scholar
Hardie R-A, van Dam E, Cowley M, Han T-L, Balaban S, Pajic M, et al. Mitochondrial mutations and metabolic adaptation in pancreatic cancer. Cancer Metab. 2017;5:2.
Google Scholar
Gentric G, Kieffer Y, Mieulet V, Goundiam O, Bonneau C, Nemati F, et al. PML-regulated mitochondrial metabolism enhances chemosensitivity in human ovarian cancers. Cell Metab. 2019;29:156–173.e10.
Google Scholar
Chia ML, Bulat F, Gaunt A, Ros S, Wright AJ, Sawle A, et al. Metabolic imaging distinguishes ovarian cancer subtypes and detects their early and variable responses to treatment. Oncogene. 2025;44:563–74.
Google Scholar
Garofano L, Migliozzi S, Oh YT, D’Angelo F, Najac RD, Ko A, et al. Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities. Nat Cancer. 2021;2:141–56.
Google Scholar
Zhang J, Sun X. Multiomics-driven drug-cell interaction network for chemotherapy sensitivity prediction in metabolically defined triple-negative breast cancer subtypes. J Cell Mol Med. 2025;29:e70572.
Google Scholar
Gold S, Shilatifard A. Epigenetic therapies targeting histone lysine methylation: complex mechanisms and clinical challenges. J Clin Invest. 2024;134:e183391.
Google Scholar
Perillo B, Tramontano A, Pezone A, Migliaccio A. LSD1: more than demethylation of histone lysine residues. Exp Mol Med. 2020;52:1936–47.
Google Scholar
Dalvi PS, Macheleidt IF, Lim S-Y, Meemboor S, Müller M, Eischeid-Scholz H, et al. LSD1 inhibition attenuates tumor growth by disrupting PLK1 mitotic pathway. Mol Cancer Res. 2019;17:1326–37.
Google Scholar
Jiang Q, Stachelscheid J, Bloehdorn J, Pacholewska A, Aszyk C, Grotenhuijs F, et al. Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia. Blood. 2023;142:44–61.
Google Scholar
Guo Y-J, Pang J-R, Zhang Y, Li Z-R, Zi X-L, Liu H-M, et al. Neddylation-dependent LSD1 destabilization inhibits the stemness and chemoresistance of gastric cancer. Int J Biol Macromol. 2024;254:126801.
Google Scholar
Chen Y, Johnson JD, Jayamohan S, He Y, Venkata PP, Jamwal D, et al. KDM1A/LSD1 inhibition enhances chemotherapy response in ovarian cancer. Mol Carcinog. 2024;63:2026–39.
Google Scholar
Sheng W, LaFleur MW, Nguyen TH, Chen S, Chakravarthy A, Conway JR, et al. LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade. Cell. 2018;174:549–563.e19.
Google Scholar
Cheng B, Xu X, Fan B, Ma T, Yu B. Epigenetic roles of lysine-specific demethylase 1 (LSD1) in cancer metabolism. Drug Discov Today. 2025;30:104397.
Google Scholar
Anan K, Hino S, Shimizu N, Sakamoto A, Nagaoka K, Takase R, et al. LSD1 mediates metabolic reprogramming by glucocorticoids during myogenic differentiation. Nucleic Acids Res. 2018;46:5441–54.
Google Scholar
Sakamoto A, Hino S, Nagaoka K, Anan K, Takase R, Matsumori H, et al. Lysine demethylase LSD1 coordinates glycolytic and mitochondrial metabolism in hepatocellular carcinoma cells. Cancer Res. 2015;75:1445–56.
Google Scholar
Song X-Q, Yu T-J, Ou-Yang Y, Ding J-H, Jiang Y-Z, Shao Z-M, et al. Copy number amplification of FLAD1 promotes the progression of triple-negative breast cancer through lipid metabolism. Nat Commun. 2025;16:1241.
Google Scholar
Ferrarese R, Izzo A, Andrieux G, Lagies S, Bartmuss JP, Masilamani AP, et al. ZBTB18 inhibits SREBP-dependent lipid synthesis by halting CTBPs and LSD1 activity in glioblastoma. Life Sci Alliance. 2023;6:e202201400.
Google Scholar
Peng C, Zhang X, Zhou N, Hu T, Shen Y, Chen TJ, et al. Apigenin inhibits lipid metabolism of hepatocellular carcinoma cells by targeting the histone demethylase KDM1A. Phytomedicine. 2024;135:156024.
Google Scholar
Pavlova NN, Zhu J, Thompson CB. The hallmarks of cancer metabolism: still emerging. Cell Metab. 2022;34:355–77.
Google Scholar
Wang Z, Liu F, Fan N, Zhou C, Li D, Macvicar T, et al. Targeting glutaminolysis: new perspectives to understand cancer development and novel strategies for potential target therapies. Front Oncol. 2020;10:589508.
Google Scholar
De Santis MC, Bockorny B, Hirsch E, Cappello P, Martini M. Exploiting pancreatic cancer metabolism: challenges and opportunities. Trends Mol Med. 2024;30:592–604.
Google Scholar
Hou X, Li Q, Yang L, Yang Z, He J, Li Q, et al. KDM1A and KDM3A promote tumor growth by upregulating cell cycle-associated genes in pancreatic cancer. Exp Biol Med. 2021;246:1869–83.
Google Scholar
Qin Y, Zhu W, Xu W, Zhang B, Shi S, Ji S, et al. LSD1 sustains pancreatic cancer growth via maintaining HIF1α-dependent glycolytic process. Cancer Lett. 2014;347:225–32.
Google Scholar
Huang R, Cai Y, Chen Q, Sun Y, Lian M, Lian M, et al. KDM1A acts as an oncogene and facilitates the epithelial mesenchymal transition process in gastric cancer. J Biochem Mol Toxicol. 2025;39:e70120.
Google Scholar
Liu J, Feng J, Li L, Lin L, Ji J, Lin C, et al. Arginine methylation-dependent LSD1 stability promotes invasion and metastasis of breast cancer. EMBO Rep. 2020;21:e48597.
Google Scholar
Jin P, Jiang J, Zhou L, Huang Z, Nice EC, Huang C, et al. Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management. J Hematol Oncol. 2022;15:97.
Google Scholar
Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17:395–417.
Google Scholar
Yuan TL, Amzallag A, Bagni R, Yi M, Afghani S, Burgan W, et al. Differential effector engagement by oncogenic KRAS. Cell Rep. 2018;22:1889–902.
Google Scholar
Mullen AR, Wheaton WW, Jin ES, Chen P-H, Sullivan LB, Cheng T, et al. Reductive carboxylation supports growth in tumor cells with defective mitochondria. Nature. 2011;481:385–8.
Google Scholar
Peng J, Sun B-F, Chen C-Y, Zhou J-Y, Chen Y-S, Chen H, et al. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Cell Res. 2019;29:725–38.
Google Scholar
Kim KH, Lee CB. Socialized mitochondria: mitonuclear crosstalk in stress. Exp Mol Med. 2024;56:1033–42.
Google Scholar
Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N, et al. A gene expression signature associated with ‘K-Ras addiction’ reveals regulators of EMT and tumor cell survival. Cancer Cell. 2009;15:489–500.
Google Scholar
Williams HL, Dias Costa A, Zhang J, Raghavan S, Winter PS, Kapner KS, et al. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. Cancer Res. 2023;83:441–55.
Google Scholar
Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SGH, Hoadley KA, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47:1168–78.
Google Scholar
Picca A, Faitg J, Auwerx J, Ferrucci L, D’Amico D. Mitophagy in human health, ageing and disease. Nat Metab. 2023;5:2047–61.
Google Scholar
Akada M, Crnogorac-Jurcevic T, Lattimore S, Mahon P, Lopes R, Sunamura M, et al. Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clin Cancer Res. 2005;11:3094–101.
Google Scholar
Erkan M, Kleeff J, Esposito I, Giese T, Ketterer K, Büchler MW, et al. Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene. 2005;24:4421–32.
Google Scholar
Yamashita S, Sugiura Y, Matsuoka Y, Maeda R, Inoue K, Furukawa K, et al. Mitophagy mediated by BNIP3 and NIX protects against ferroptosis by downregulating mitochondrial reactive oxygen species. Cell Death Differ. 2024;31:651–61.
Google Scholar
Chourasia AH, Tracy K, Frankenberger C, Boland ML, Sharifi MN, Drake LE, et al. Mitophagy defects arising from BNip3 loss promote mammary tumor progression to metastasis. EMBO Rep. 2015;16:1145–63.
Google Scholar
Humpton TJ, Alagesan B, DeNicola GM, Lu D, Yordanov GN, Leonhardt CS, et al. Oncogenic KRAS induces NIX-mediated mitophagy to promote pancreatic cancer. Cancer Discov. 2019;9:1268–87.
Google Scholar
Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sánchez N, Marchesini M, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014;514:628–32.
Google Scholar
Kerr E, Gaude E, Turrell F, Frezza C, Martins CP. Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities. Nature. 2016;531:110–3.
Google Scholar
Bornstein R, Mulholland MT, Sedensky M, Morgan P, Johnson SC. Glutamine metabolism in diseases associated with mitochondrial dysfunction. Mol Cell Neurosci. 2023;126:103887.
Google Scholar
Buczkowska J, Szeliga M. Two faces of glutaminase GLS2 in carcinogenesis. Cancers. 2023;15:5566.
Google Scholar
Saha SK, Islam SMR, Abdullah-AL-Wadud M, Islam S, Ali F, Park KS. Multiomics analysis reveals that GLS and GLS2 differentially modulate the clinical outcomes of cancer. J Clin Med. 2019;8:355.
Google Scholar
Suzuki S, Venkatesh D, Kanda H, Nakayama A, Hosokawa H, Lee E, et al. GLS2 is a tumor suppressor and a regulator of ferroptosis in hepatocellular carcinoma. Cancer Res. 2022;82:3209–22.
Google Scholar
Veeramachaneni RK, Suter RK, Rowland E, Jermakowicz A, Ayad NG. Glutaminase 2 as a therapeutic target in glioblastoma. Biochim Biophys Acta Rev Cancer. 2024;1879:189182.
Google Scholar
Lukey MJ, Cluntun AA, Katt WP, Lin MJ, Druso JE, Ramachandran S, et al. Liver-type glutaminase GLS2 is a druggable metabolic node in luminal-subtype breast cancer. Cell Rep. 2019;29:76–88.e7.
Google Scholar
Chen X, Fu H, Zhu S, Xiang Z, Fu H, Sun Z, et al. The Moonlighting function of glutaminase 2 promotes immune evasion of pancreatic ductal adenocarcinoma by tubulin tyrosine ligase-like 1-mediated Yes1 associated transcriptional regulator glutamylation. Gastroenterology. 2025;168:1137–52.
Google Scholar
Zhang Z, Li H, Deng Y, Schuck K, Raulefs S, Maeritz N, et al. AGR2-dependent nuclear import of RNA polymerase II constitutes a specific target of pancreatic ductal adenocarcinoma in the context of wild-type p53. Gastroenterology. 2021;161:1601–1614.e23.
Google Scholar
Kong B, Wu W, Cheng T, Schlitter AM, Qian C, Bruns P, et al. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling. Gut. 2016;65:647–57.
Google Scholar
Lim S-Y, Macheleidt I, Dalvi P, Schäfer SC, Kerick M, Ozretić L, et al. LSD1 modulates the non-canonical integrin β3 signaling pathway in non-small cell lung carcinoma cells. Sci Rep. 2017;7:10292.
Google Scholar
